Current Issue

October 2025

From Microscopes to AI

In the last 10 years, hematopathologists have seen dynamic transformations in everything from diagnosis to data analysis.

Viewpoints

Editor’s Corner

Stepping Into Tomorrow: Genomics, AI, and the Blood Science Revolution

Education

You Make the Call

You Make the Call: What antithrombotic therapy do you recommend for a large hematoma with multiple comorbidities?

You Make the Call: Reader's Response

What antithrombotic therapy do you recommend for a large hematoma with multiple comorbidities?

Hematologica Obscura

Rare WHIM Syndrome Intersects With Broader Issues in Hematology and Beyond

Spotlight

Feature Articles

From Microscopes to AI

The Search for Research

The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW) (NCT06499285)

News

PDUFA Pending

Revumenib Looks to Fill a Therapeutic Void for Patients With R/R NPM1-Mutated AML

In a Different Vein: News from the Blood Journals

Quadruplet Induction Therapy for MM Achieves High Rate of MRD Negativity in MIDAS Trial
ASAP Trial Challenges Standard Practice of Remission Induction Before Transplant in AML
Talquetamab Bridging Therapy Enables Transition to BCMA CAR-T for Patients With High-Risk Myeloma

Literature Scan

p53 IHC Testing May Be Reliable Surrogate for Early Identification of TP53-Mutated MDS, AML
Study Shows Modest Increased Risk of VTE in Patients With CHIP
Intermediate Dose of Cytarabine as Effective as Higher Dose for Post-Induction in AML

ASH Directions

ASH Awards Bridge Grants to Support 25 Research Projects

Data Stream

October 2025 Data Stream

Online Only

Literature Scan

EMD Linked to Severe Toxicities After CAR T-Cell Therapy in MM

The Search for Research

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (NCT05554393)